Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer

被引：0
|
作者：
El-Rayes B
Shields, A.
Zalupski, M.
Bekaii-Saab, T.
Heilbrun, L.
Vaishampayan, U.
Manza, S.
机构：
[1] Karmanos Canc Ctr, Dearborn, MI USA
[2] Univ Michigan, Detroit, MI USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.
    El-Rayes, BF
    Shields, AF
    Vaishampayan, U
    Heilbrun, L
    Bekaii-Saab, T
    Zalupski, MM
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [2] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    Bassel F. El-Rayes
    Mark M. Zalupski
    Stephanie G. Manza
    Barbara Rusin
    Ann Marie Ferris
    Ulka Vaishampayan
    Lance K. Heilbrun
    Raghu Venkatramanamoorthy
    Anthony F. Shields
    Philip A. Philip
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 283 - 289
  • [3] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    El-Rayes, Bassel F.
    Zalupski, Mark M.
    Manza, Stephanie G.
    Rusin, Barbara
    Ferris, Ann Marie
    Vaishampayan, Ulka
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Shields, Anthony F.
    Philip, Philip A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 283 - 289
  • [4] A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer.
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Heilbrun, LK
    Bekaii-Saab, T
    Vaishampayan, U
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 290S - 290S
  • [5] Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC)
    Ahn, JB
    Jung, KH
    Park, YS
    Kim, YH
    Chang, HJ
    Sohn, DK
    Lim, SB
    Choi, HS
    Jeong, SY
    Park, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 299S - 299S
  • [6] Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients.
    Li, Wenhua
    Li, Jin
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Wei Jian
    Zhang, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
    Maroun, Jean
    Marginean, Horia
    Jonker, Derek
    Cripps, Christine
    Goel, Rakesh
    Asmis, Timothy
    Goodwin, Rachel
    Chiritescu, Gabriela
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E257 - E268
  • [8] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Caputo, G.
    Novello, G.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 781 - 786
  • [9] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study
    Price, T. J.
    Townsend, A. R.
    Khattak, A.
    ANNALS OF ONCOLOGY, 2010, 21 (10) : 2121 - 2121
  • [10] Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer
    Pavia, OA
    Cangiano, J
    Crisostomo, R
    Caceres, W
    Barranco, E
    Wright, M
    Antonia, T
    Antonia, S
    Sullivan, D
    Garrett, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 307S - 307S
12345